Literature DB >> 9425362

dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess.

K K Seymour1, A E Yeo, K H Rieckmann, R I Christopherson.   

Abstract

The pyrimidine antagonists, 6-L-thiodihydroorotate (TDHO) and atovaquone, are known to induce inhibition of de-novo pyrimidine biosynthesis in Plasmodium falciparum growing in erythrocytic culture, at reactions catalysed by dihydroorotase and dihydroorotate dehydrogenase, respectively. In the present study, TDHO and atovaquone induced decreases in the levels of UTP, CTP and dTTP but not dCTP in P. falciparum. Addition of orotate with either antagonist increased UTP, CTP and dTTP but depressed GTP, ATP, dATP and dCTP, suggesting that these drugs indirectly modulate the activity of ribonucleotide reductase. The changes induced in the levels of dNTP by these pyrimidine antagonists are similar to those previously described for the antifolates, cycloguanil and WR99210.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9425362     DOI: 10.1080/00034989760699

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  6 in total

Review 1.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Authors:  Margaret A Phillips; Pradipsinh K Rathod
Journal:  Infect Disord Drug Targets       Date:  2010-06

2.  Stage-specific requirement of a mitogen-activated protein kinase by Trypanosoma brucei.

Authors:  Ingrid B Müller; Debora Domenicali-Pfister; Isabel Roditi; Erik Vassella
Journal:  Mol Biol Cell       Date:  2002-11       Impact factor: 4.138

3.  Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis.

Authors:  Carola Huthmacher; Andreas Hoppe; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  BMC Syst Biol       Date:  2010-08-31

4.  Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria.

Authors:  Giancarlo A Biagini; Nicholas Fisher; Alison E Shone; Murad A Mubaraki; Abhishek Srivastava; Alisdair Hill; Thomas Antoine; Ashley J Warman; Jill Davies; Chandrakala Pidathala; Richard K Amewu; Suet C Leung; Raman Sharma; Peter Gibbons; David W Hong; Bénédicte Pacorel; Alexandre S Lawrenson; Sitthivut Charoensutthivarakul; Lee Taylor; Olivier Berger; Alison Mbekeani; Paul A Stocks; Gemma L Nixon; James Chadwick; Janet Hemingway; Michael J Delves; Robert E Sinden; Anne-Marie Zeeman; Clemens H M Kocken; Neil G Berry; Paul M O'Neill; Stephen A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

5.  Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression.

Authors:  Nicholas Fisher; Roslaini Abd Majid; Thomas Antoine; Mohammed Al-Helal; Ashley J Warman; David J Johnson; Alexandre S Lawrenson; Hilary Ranson; Paul M O'Neill; Stephen A Ward; Giancarlo A Biagini
Journal:  J Biol Chem       Date:  2012-01-26       Impact factor: 5.157

Review 6.  Antimalarial pharmacology and therapeutics of atovaquone.

Authors:  Gemma L Nixon; Darren M Moss; Alison E Shone; David G Lalloo; Nicholas Fisher; Paul M O'Neill; Stephen A Ward; Giancarlo A Biagini
Journal:  J Antimicrob Chemother       Date:  2013-01-04       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.